Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.

Miyamura T, Kanda T, Nakamoto S, Wu S, Jiang X, Arai M, Fujiwara K, Imazeki F, Yokosuka O.

Viruses. 2012 Aug;4(8):1264-78. doi: 10.3390/v4081264. Epub 2012 Aug 14.

2.

ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.

Matsuura K, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, Kusakabe A, Shinkai N, Nojiri S, Joh T, Mizokami M.

J Viral Hepat. 2014 Jul;21(7):466-74. doi: 10.1111/jvh.12171. Epub 2013 Sep 3.

PMID:
24750345
3.

Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population.

Sghaier I, Mouelhi L, Gazouani E, Morel V, Besma YL, Brochot E.

J Clin Virol. 2015 Aug;69:184-9. doi: 10.1016/j.jcv.2015.06.102. Epub 2015 Jun 27.

PMID:
26209404
4.

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.

Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Matsuura K, Sugauchi F, Enomoto N, Nishida N, Tokunaga K, Mizokami M, Izumi N.

Antivir Ther. 2011;16(5):685-94. doi: 10.3851/IMP1796.

PMID:
21817190
5.

Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.

Scherzer TM, Stättermayer AF, Stauber R, Maieron A, Strasser M, Laferl H, Schwarzer R, Datz C, Rutter K, Beinhardt S, Steindl-Munda P, Hofer H, Ferenci P.

J Hepatol. 2013 Nov;59(5):964-71. doi: 10.1016/j.jhep.2013.06.030. Epub 2013 Jul 10.

PMID:
23850877
6.

Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.

Seto WK, Tsang OT, Liu K, Chan JM, Wong DK, Fung J, Lai CL, Yuen MF.

J Viral Hepat. 2013 Jul;20(7):470-7. doi: 10.1111/jvh.12047. Epub 2013 Apr 12.

PMID:
23730840
7.

Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.

Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Okada K, Kainuma M, Kajiwara E, Takahashi K, Satoh T, Hayashi J.

J Viral Hepat. 2013 Dec;20(12):838-46. doi: 10.1111/jvh.12109. Epub 2013 May 26.

PMID:
24304453
8.

No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.

Heo NY, Lim YS, Lee W, Oh M, An J, Lee D, Shim JH, Kim KM, Lee HC, Lee YS, Suh DJ.

Clin Mol Hepatol. 2014 Jun;20(2):177-84. doi: 10.3350/cmh.2014.20.2.177. Epub 2014 Jun 30.

9.

The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.

Kim JS, Ahn SM, Jung YK, Kwon OS, Kim YS, Choi DJ, Kim JH.

J Korean Med Sci. 2013 Aug;28(8):1213-9. doi: 10.3346/jkms.2013.28.8.1213. Epub 2013 Jul 31.

10.

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.

Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM.

AIDS. 2011 May 15;25(8):1025-33. doi: 10.1097/QAD.0b013e3283471cae.

11.

Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.

Nishimura T, Osaki R, Shioya M, Imaeda H, Aomatsu T, Takeuchi T, Okumura Y, Fujiyama Y, Andoh A.

Mol Med Rep. 2012 Feb;5(2):517-20. doi: 10.3892/mmr.2011.659. Epub 2011 Nov 2.

PMID:
22052220
12.

Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.

D'Avolio A, De Nicolò A, Cusato J, Ciancio A, Boglione L, Strona S, Cariti G, Troshina G, Caviglia GP, Smedile A, Rizzetto M, Di Perri G.

Antiviral Res. 2013 Oct;100(1):114-9. doi: 10.1016/j.antiviral.2013.07.021. Epub 2013 Aug 8.

13.

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.

Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.

J Viral Hepat. 2014 Mar;21(3):178-88. doi: 10.1111/jvh.12128. Epub 2013 Jul 17.

PMID:
24438679
14.

Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?

Veillon P, Fouchard-Hubert I, Larrey D, Dao MT, D'alteroche L, Boyer-Darrigand N, Picard N, Le Guillou-Guillemette H, Saulnier P, Ducancelle A, Loustaud-Ratti V, Lunel-Fabiani F.

J Interferon Cytokine Res. 2016 Mar;36(3):204-14. doi: 10.1089/jir.2015.0131. Epub 2015 Dec 24.

PMID:
26700738
15.

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.

Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.

Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14.

PMID:
24102823
16.

Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.

Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20.

17.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
18.

Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection.

Kamal AM, MitruŢ P, Kamal KC, Tica OS, Niculescu M, Alexandru DO, Tica AA.

Rom J Morphol Embryol. 2016;57(2 Suppl):675-680.

19.

Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.

Amanzada A, Schneider S, Moriconi F, Lindhorst A, Suermann T, van Thiel DH, Mihm S, Ramadori G.

J Med Virol. 2012 Aug;84(8):1208-16. doi: 10.1002/jmv.23323.

PMID:
22711348
20.

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.

Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K.

J Med Virol. 2011 Jun;83(6):1048-57. doi: 10.1002/jmv.22069.

PMID:
21503919

Supplemental Content

Support Center